Elisabeth Solau-Gervais

TL;DR: Among patients with rheumatoid arthritis previously treated with anti-T NF drugs but with inadequate primary response, a non-TNF biologic agent was more effective in achieving a good or moderate disease activity response at 24 weeks than was the second anti- TNF medication.

TL;DR: In patients receiving anti-TNF-alpha who develop pneumonia, legionellosis should be systematically investigated, and first-line antibiotic therapy should be efficient against L. pneumophila.

TL;DR: Kits using citrullinated cyclic peptides (CCP2) were more suitable than either AKA or EIA using linear filaggrin peptides for the diagnosis of early rheumatoid disease.

TL;DR: It is indicated that continuous treatment of ankylosing spondylitis with infliximab is more efficacious than on-demand treatment, and that the addition of MTX to inflIXimab provides no significant benefit.

TL;DR: There are too few reports of exposure during pregnancy to allow any conclusion about the safety of TNF blockers, and additional long term follow-up of children would be welcome in order to rule out minor forms of VACTERL association that might have been overlooked at birth.